Skip to main content
. Author manuscript; available in PMC: 2007 May 8.
Published in final edited form as: Nat Immunol. 2007 Mar;8(3):219–222. doi: 10.1038/ni0307-219

Figure 2.

Figure 2

Possible influence of CCL3 and CCL3L1 genotype on the development of adaptive immunity to HIV vaccines and restoration of loss of function in people with deficient production through the provision of CCL3 as adjuvant. CCL3 and CCL3L1 genotype determines the production phenotype as being wild-type (WT) or deficient (red arrowheads). Left, wild-type production of CCL3 as the critical component of a rapid innate immune response (red line) that ‘instructs’ the effective development of subsequent adaptive immunity (green line). Middle, deficient production of CCL3 ‘translates’ into an ineffective adaptive immune response. Right, provision of CCL3 as an adjuvant (blue line) compensates for deficient host production and restores the development of adaptive immunity to wild-type capability (dashed green line).